Canada - English - Health Canada

teva canada limited - galantamine (galantamine hydrobromide) - capsule (extended release) - 8mg - galantamine (galantamine hydrobromide) 8mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

teva canada limited - galantamine (galantamine hydrobromide) - capsule (extended release) - 16mg - galantamine (galantamine hydrobromide) 16mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

teva canada limited - galantamine (galantamine hydrobromide) - capsule (extended release) - 24mg - galantamine (galantamine hydrobromide) 24mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

pro doc limitee - galantamine (galantamine hydrobromide) - capsule (extended release) - 8mg - galantamine (galantamine hydrobromide) 8mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

pro doc limitee - galantamine (galantamine hydrobromide) - capsule (extended release) - 16mg - galantamine (galantamine hydrobromide) 16mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

pro doc limitee - galantamine (galantamine hydrobromide) - capsule (extended release) - 24mg - galantamine (galantamine hydrobromide) 24mg - parasympathomemetic (cholinergic) agents

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: indigo carmine; iron oxide red; erythrosine; gelatin; hypromellose; magnesium stearate; titanium dioxide; iron oxide yellow; microcrystalline cellulose; ethylcellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; titanium dioxide; microcrystalline cellulose; iron oxide red; magnesium stearate; hypromellose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: hypromellose; gelatin; magnesium stearate; microcrystalline cellulose; ethylcellulose; titanium dioxide - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

United States - English - NLM (National Library of Medicine)

rebel distributors corp - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine hydrobromide 8 mg - razadyne® er/razadyne® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the alzheimer's type. razadyne® er/razadyne® (galantamine hydrobromide) is contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.